ESSA Pharma (EPIX) Competitors $0.20 0.00 (-1.85%) Closing price 04:00 PM EasternExtended Trading$0.20 0.00 (-2.09%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPIX vs. EGRX, SONN, RVPH, ATHE, PLUR, ELUT, MAAQ, OKUR, RANI, and MURAShould you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Eagle Pharmaceuticals (EGRX), Sonnet BioTherapeutics (SONN), Reviva Pharmaceuticals (RVPH), Alterity Therapeutics (ATHE), Pluri (PLUR), Elutia (ELUT), Mana Capital Acquisition (MAAQ), OnKure Therapeutics (OKUR), Rani Therapeutics (RANI), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry. ESSA Pharma vs. Its Competitors Eagle Pharmaceuticals Sonnet BioTherapeutics Reviva Pharmaceuticals Alterity Therapeutics Pluri Elutia Mana Capital Acquisition OnKure Therapeutics Rani Therapeutics Mural Oncology ESSA Pharma (NASDAQ:EPIX) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Which has more risk and volatility, EPIX or EGRX? ESSA Pharma has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Which has preferable valuation & earnings, EPIX or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than ESSA Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioESSA PharmaN/AN/A-$28.54M-$0.56-0.36Eagle Pharmaceuticals$257.55M0.15$35.64MN/AN/A Does the media prefer EPIX or EGRX? In the previous week, ESSA Pharma had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for ESSA Pharma and 1 mentions for Eagle Pharmaceuticals. ESSA Pharma's average media sentiment score of 0.94 beat Eagle Pharmaceuticals' score of 0.00 indicating that ESSA Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ESSA Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eagle Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate EPIX or EGRX? ESSA Pharma currently has a consensus target price of $2.00, indicating a potential upside of 894.04%. Given ESSA Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe ESSA Pharma is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ESSA Pharma 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals have more ownership in EPIX or EGRX? 75.1% of ESSA Pharma shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 15.5% of ESSA Pharma shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is EPIX or EGRX more profitable? Eagle Pharmaceuticals' return on equity of 0.00% beat ESSA Pharma's return on equity.Company Net Margins Return on Equity Return on Assets ESSA PharmaN/A -21.71% -21.22% Eagle Pharmaceuticals N/A N/A N/A SummaryEagle Pharmaceuticals beats ESSA Pharma on 6 of the 11 factors compared between the two stocks. Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPIX vs. The Competition Export to ExcelMetricESSA PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.52M$2.64B$6.10B$10.65BDividend Yield828.12%56.92%5.70%4.74%P/E Ratio-0.3623.6985.5527.59Price / SalesN/A785.33622.26138.47Price / CashN/A169.9037.7861.77Price / Book0.075.5313.136.76Net Income-$28.54M$32.78M$3.30B$275.88M7 Day Performance-2.28%6.99%5.29%3.72%1 Month Performance-15.07%14.03%9.94%10.22%1 Year Performance-96.53%0.78%87.78%35.86% ESSA Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPIXESSA Pharma3.942 of 5 stars$0.20-1.9%$2.00+894.0%-96.7%$9.70MN/A0.0050Dividend AnnouncementAnalyst ForecastGap UpEGRXEagle Pharmaceuticals1.4809 of 5 stars$3.00flatN/A+361.5%$38.96M$257.55M0.00100High Trading VolumeSONNSonnet BioTherapeutics1.7648 of 5 stars$5.44-3.4%$20.00+267.6%+7.4%$38.44M$20K0.0010Positive NewsAnalyst ForecastRVPHReviva Pharmaceuticals3.7366 of 5 stars$0.67+22.8%$4.86+625.7%-30.6%$37.79MN/A-1.035News CoverageAnalyst ForecastGap DownHigh Trading VolumeATHEAlterity Therapeutics2.5507 of 5 stars$4.33+1.9%$12.00+177.1%+228.8%$37.69MN/A0.0010Positive NewsAnalyst ForecastPLURPluri1.7452 of 5 stars$4.31-6.5%$12.00+178.4%-15.7%$37.61M$1.34M-0.83150News CoverageAnalyst ForecastHigh Trading VolumeELUTElutia3.1118 of 5 stars$0.88+0.1%$7.00+694.3%-77.0%$37.31M$23.68M-0.83180Analyst ForecastGap UpMAAQMana Capital AcquisitionN/A$4.55+7.1%N/A-26.6%$36.97MN/A0.001Gap UpHigh Trading VolumeOKUROnKure Therapeutics3.4964 of 5 stars$2.82+4.1%$32.33+1,046.6%N/A$36.67MN/A-0.59N/AAnalyst ForecastHigh Trading VolumeRANIRani Therapeutics2.733 of 5 stars$0.51+0.1%$7.33+1,350.4%-77.9%$36.29M$1.03M-0.56110Analyst ForecastShort Interest ↓MURAMural Oncology3.4101 of 5 stars$2.08flat$12.00+476.9%-38.7%$36.04MN/A-0.24119Analyst Forecast Related Companies and Tools Related Companies Eagle Pharmaceuticals Alternatives Sonnet BioTherapeutics Alternatives Reviva Pharmaceuticals Alternatives Alterity Therapeutics Alternatives Pluri Alternatives Elutia Alternatives Mana Capital Acquisition Alternatives OnKure Therapeutics Alternatives Rani Therapeutics Alternatives Mural Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPIX) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe 'Big Beautiful Bill' That Could Break AmericaOn July 4th, they celebrated the $3.4 trillion "One Big Beautiful Bill Act." What they didn't say? This bil...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
